Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

Tuhura Biosciences Aktie News

Aktie
WKN:  A3EWMJ ISIN:  US8989201038 US-Symbol:  HURA Branche:  Biotechnologie Land:  USA
0,4482 $
-0,0156 $
-3,36%
0,37984 € 18:35:33 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,07 Mio. €
Streubesitz
51,94%
KGV
-5,37
Index-Zuordnung
-

Tuhura Biosciences News

08.04.25 - PR Newswire
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting PR Newswire
07.04.25 - PR Newswire
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management PR Newswire
01.04.25 - PR Newswire
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update PR Newswire
19.12.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders PR Newswire
16.12.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders PR Newswire
12.12.24 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA PR Newswire
16.10.24 - PR Newswire
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to ...
16.10.24 - PR Newswire
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences PR Newswire
15.10.24 - PR Newswire
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close ...
14.10.24 - PR Newswire
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 PR ...
08.10.24 - PR Newswire
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update PR Newswire
20.09.24 - PR Newswire
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 PR Newswire
18.09.24 - PR Newswire
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences PR Newswire
18.09.24 - PR Newswire
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences PR Newswire
11.09.24 - PR Newswire
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study PR Newswire
09.09.24 - PR Newswire
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. PR Newswire
19.08.24 - PR Newswire
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor ...
08.07.24 - PR Newswire
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-​VISTA Checkpoint Inhibitor PR Newswire
01.07.24 - PR Newswire
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones PR Newswire
03.06.24 - PR Newswire
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant ...

Newssuche

Videos

newspaper
10:20 Uhr +9,48%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »